In the last trading session, 1.3 million shares of the Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) were traded, and its beta was -0.67. Most recently the company’s share price was $4.51, and it changed around -$0.37 or -7.58% from the last close, which brings the market valuation of the company to $309.15M. AMLX currently trades at a discount to its 52-week high of $19.95, offering almost -342.35% off that amount. The share price’s 52-week low was $1.58, which indicates that the current value has risen by an impressive 64.97% since then. We note from Amylyx Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.65 million shares, with the 3-month average coming to 1.45 million.
Amylyx Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.17. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 4 recommended AMLX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Amylyx Pharmaceuticals Inc is expected to report earnings per share of -0.6 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Instantly AMLX has showed a red trend with a performance of -7.58% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.50 on recent trading dayincreased the stock’s daily price by 18.0%. The company’s shares are currently down -69.36% year-to-date, but still down -15.70% over the last five days. On the other hand, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is -32.69% down in the 30-day period. We can see from the shorts that 1.53 million shares have been sold at a short interest cover period of 0.82 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 49.89% from its current value. Analyst projections state that AMLX is forecast to be at a low of $4 and a high of $11.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
Amylyx Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 159.20 percent over the past six months and at a -712.86% annual growth rate that is well below the industry average of 16.70%. The year-over-year growth rate is expected to be -76.88%, down from the previous year.
The company’s sales for the same quarters a year ago were 108.45M and 88.64M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at -100.00%.
AMLX Dividends
Amylyx Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in January.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.30% of Amylyx Pharmaceuticals Inc shares, and 82.51% of them are in the hands of institutional investors. The stock currently has a share float of 96.28%. Amylyx Pharmaceuticals Inc stock is held by 156.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 6.2251% of the shares, which is about 4.22 million shares worth $8.03 million.
AQR CAPITAL MANAGEMENT LLC, with 4.9237% or 3.34 million shares worth $6.35 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
